CILP-1 Is a Biomarker for Backward Failure and Right Ventricular Dysfunction in HFrEF.

Background: CILP-1 regulates myocardial fibrotic response and remodeling and was reported to indicate right ventricular dysfunction (RVD) in pulmonary hypertension (PH) and heart failure (HF). This study examines CILP-1 as a potential biomarker for RVD and prognosis in heart failure with reduced ejection fraction (HFrEF) patients on guideline-directed medical therapy.

Methods: CILP-1 levels were measured in 610 HFrEF patients from a prospective registry with biobanking (2016-2022).